Showing 3981-3990 of 5623 results for "".
- Parexel Enters Agreement with MyEyeDr to Refer Patients into Existing and Future Ophthalmology Clinical Trialshttps://modernod.com/news/parexel-enters-agreement-with-myeyedr-to-refer-patients-into-existing-and-future-ophthalmology-clinical-trials/2481298/Parexel, a clinical research organization (CRO), announced a formal agreement with MyEyeDr to refer its patients into existing and future ophthalmology clinical trials. Terms of the deal were not disclosed. Parexel and MyEyeDr are currently collaborating on recruitme
- AI-Diagnostics Startup Altris AI Raises $1 Million to Scale AI-Based Eye Care Diagnostics Platformhttps://modernod.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/Altris AI announced it has raised $1 million to scale its AI-enabled eye care diagnostics solution. Altris AI, which is a US-based startup originally from Ukraine, developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies an
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t
- Harrow Enters Into Agreement to Acquire Exclusive US Rights to Five Ophthalmic Products from Novartishttps://modernod.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/Harrow announced it has entered into a agreement for the acquisition of the exclusive US commercial rights to five FDA‑approved ophthalmic products from Novartis in a deal worth up to $175 million. This transaction, which is the second acquisition transaction between Har
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilationhttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-dilation/2481289/Eyenovia announced that the FDA has accepted for review the company’s new drug application (NDA) for MydCombi ophthalmic spray. MydCombi is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phe
- Nidek Launches Fully Assisted Refraction System for TS-610https://modernod.com/news/nidek-launches-fully-assisted-refraction-system-for-ts-610/2481287/Nidek has announced the launch of the Fully Assisted Refraction System (FARS), an optional kit for the TS-610 Nidek Tabletop Refraction System. allowing for subjective refractions that integrate the chart and refractor into a single unit. FARS is used to determine th
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D
- Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice Presidenthttps://modernod.com/news/eyenovia-announces-promotion-of-bren-kern-to-chief-operating-officer-and-corporate-vice-president/2481283/Eyenovia announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1. “Since joining the company earlier this year, Bren has
- Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primateshttps://modernod.com/news/aviceda-announces-successful-completion-of-key-ind-toxicity-milestone-with-favorable-safety-profile-in-non-human-primates/2481280/Aviceda Therapeutics announced completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. Cambridge, Massachusetts-based Aviceda, has developed a proprietary nano-technology HALOS&
- Sifi Launches EpiColin Glaucoma Supplement in Italyhttps://modernod.com/news/sifi-launches-epicolin-glaucoma-supplement-in-italy/2481276/Sifi announced the launch in Italy of EpiColin, a food supplement dedicated to patients suffering from glaucoma. Following Amiriox and Ecbirio, IOP drugs fully reimbursed by the Italian NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by Sifi in th